All In Biotech

Drug Trial Radar · NCT06732648

The Efficacy and Safety of HRS8179 in Severe Cerebral Edema Following Large Hemispheric Infarction

The Efficacy and Safety of Intravenous HRS8179 for the Prevention and Treatment of Severe Cerebral Edema Following Large Hemispheric Infarction: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II/III Clinical Trial

Last checked: Nov 20, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 725 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

725

Planned (sponsor's estimate)

Start

Feb 7, 2025

Primary completion

Jun 2027

Study completion Sep 2027

Sponsor

Sponsor type
Industry
First posted
Dec 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy, and safety of HRS8179 injection in preventing and treating severe cerebral edema after large area cerebral infarction in the cerebral hemisphere

Conditions

  • Severe Cerebral Edema Following Large Hemispheric Infarction

Interventions

  • HRS8179 injectionDrug

    HRS8179 injection; high dose

  • HRS8179 blank preparation.Drug

    HRS8179 blank preparation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mortality rate at Day 90Time frame: at Day 90

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.